Skip to main content

Table 2 Pharmacokinetic parameters estimated from literature

From: The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib

  

ka

ke

Dc

Ï„c

VdS−1F−1a

Imatinib

[49]

20

0.86

810

1

0.24

Nilotinib

[50]

30

1.5

760

0.5

0.31

Dasatinib

[51]

21

5.2

200

1

1.3

Bosutinib

[52]

10

0.71

750

1

2.5

Ponatinib

[53]

11

0.76

84

1

0.50

Axitinib

[54]

23

4.1

13 b

1

0.15

Asciminib

[55]

27

1.6

88 b

1

0.076

  1. aCalculated as one variable during parametrization
  2. bEstimates of a tolerable dose. No standard doses have been established as these are not conventional treatments
  3. cFrom standard treatment [56]
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us